
## Loren L Flynn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/119433/publications.pdf Version: 2024-02-01



LODEN L FLYNN

#	ARTICLE	IF	CITATIONS
1	Short structural variants as informative genetic markers for ALS disease risk and progression. BMC Medicine, 2022, 20, 11.	5.5	4
2	Single Stranded Fully Modified-Phosphorothioate Oligonucleotides can Induce Structured Nuclear Inclusions, Alter Nuclear Protein Localization and Disturb the Transcriptome In Vitro. Frontiers in Genetics, 2022, 13, 791416.	2.3	10
3	Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience, 2021, 13, 658226.	3.4	38
4	Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. Biomedicines, 2021, 9, 552.	3.2	6
5	p62 overexpression induces TDP-43 cytoplasmic mislocalisation, aggregation and cleavage and neuronal death. Scientific Reports, 2021, 11, 11474.	3.3	19
6	Disease-modifying effects of an <i>SCAF4</i> structural variant in a predominantly <i>SOD1</i> ALS cohort. Neurology: Genetics, 2020, 6, e470.	1.9	9
7	Association of a structural variant within the <i>SQSTM1</i> gene with amyotrophic lateral sclerosis. Neurology: Genetics, 2020, 6, e406.	1.9	9
8	Structural Variants May Be a Source of Missing Heritability in sALS. Frontiers in Neuroscience, 2020, 14, 47.	2.8	43
9	Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides. International Journal of Molecular Sciences, 2019, 20, 5030.	4.1	14
10	ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?. Frontiers in Neuroscience, 2019, 13, 1310.	2.8	487
11	Antisense-mediated splice intervention to treat human disease: the odyssey continues. F1000Research, 2019, 8, 710.	1.6	11
12	Antisense Oligonucleotide-Mediated Terminal Intron Retention of the SMN2 Transcript. Molecular Therapy - Nucleic Acids, 2018, 11, 91-102.	5.1	16